Viridian Therapeutics, INC.\De (VRDN) — 8-K Filings

8-K Filings (25)

• 8-K Filing — Mar 30, 2026
• Viridian Therapeutics Files 8-K on Financials — Nov 5, 2025 Risk: low
  Viridian Therapeutics, Inc. filed an 8-K on November 5, 2025, reporting on its results of operations and financial condition. The filing also includes financial
• Viridian Therapeutics Enters Material Definitive Agreement — Oct 23, 2025 Risk: medium
  On October 21, 2025, Viridian Therapeutics, Inc. entered into a material definitive agreement. The filing also includes financial statements and exhibits relate
• Viridian Therapeutics Files 8-K on Financials — Oct 21, 2025 Risk: low
  Viridian Therapeutics, Inc. filed an 8-K on October 21, 2025, reporting on its results of operations and financial condition. The company, formerly known as Mir
• Viridian Therapeutics Enters Material Definitive Agreement — Oct 20, 2025 Risk: medium
  Viridian Therapeutics, Inc. entered into a Material Definitive Agreement on October 17, 2025. The filing does not specify the other party or the nature of the a
• Viridian Therapeutics Files 8-K on Financials — Aug 6, 2025 Risk: low
  Viridian Therapeutics, Inc. filed an 8-K on August 6, 2025, reporting on its results of operations and financial condition. The filing also includes financial s
• Viridian Therapeutics Files 8-K: Material Agreement Announced — Jul 30, 2025 Risk: medium
  Viridian Therapeutics, Inc. announced on July 30, 2025, that it entered into a Material Definitive Agreement. The company also disclosed information related to
• Viridian Therapeutics Files 8-K on Officer/Director Changes — Jun 24, 2025 Risk: medium
  Viridian Therapeutics, Inc. filed an 8-K on June 24, 2025, reporting events as of June 20, 2025. The filing indicates changes related to the departure of direct
• Viridian Therapeutics Files 8-K — May 20, 2025 Risk: low
  Viridian Therapeutics, Inc. filed an 8-K on May 20, 2025, reporting under Regulation FD and including financial statements and exhibits. The company, formerly k
• Viridian Therapeutics Files 8-K on Financials — May 6, 2025 Risk: low
  Viridian Therapeutics, Inc. filed an 8-K on May 6, 2025, reporting on its results of operations and financial condition, as well as financial statements and exh
• Viridian Therapeutics Board Changes & Filings — Apr 7, 2025 Risk: low
  Viridian Therapeutics, Inc. announced on April 2, 2025, the departure of Dr. Jonathan G. Drachman from its Board of Directors. The company also reported on comp
• Viridian Therapeutics Announces Board and Executive Changes — Mar 10, 2025 Risk: medium
  Viridian Therapeutics, Inc. announced on March 5, 2025, changes in its board of directors and executive compensation arrangements. Specifically, the company ele
• Viridian Therapeutics Terminates Material Definitive Agreement — Mar 4, 2025 Risk: medium
  Viridian Therapeutics, Inc. announced on March 3, 2025, the termination of a material definitive agreement. The company, formerly known as Miragen Therapeutics,
• Viridian Therapeutics Files 8-K on Financials — Feb 27, 2025 Risk: low
  Viridian Therapeutics, Inc. filed an 8-K on February 27, 2025, reporting on its results of operations and financial condition, as well as financial statements a
• Viridian Therapeutics Announces Board and Officer Changes — Jan 10, 2025 Risk: medium
  Viridian Therapeutics, Inc. announced on January 7, 2025, a change in its board of directors. Specifically, the company reported the departure of certain office
• Takeda to Acquire Viridian Therapeutics for $1 Billion — Dec 16, 2024 Risk: medium
  Viridian Therapeutics, Inc. announced on December 16, 2024, that it has entered into a definitive agreement to be acquired by Shire B.V., a subsidiary of Takeda
• Viridian Therapeutics Files 8-K on Financials — Nov 12, 2024 Risk: low
  Viridian Therapeutics, Inc. filed an 8-K on November 12, 2024, reporting on its results of operations and financial condition. The filing also includes Regulati
• Viridian Therapeutics Enters Material Definitive Agreement — Sep 12, 2024 Risk: medium
  Viridian Therapeutics, Inc. announced on September 11, 2024, that it entered into a Material Definitive Agreement. The filing does not provide specific details
• Shire to Acquire Viridian Therapeutics for $1 Billion — Sep 10, 2024 Risk: medium
  Viridian Therapeutics, Inc. announced on September 10, 2024, that it has entered into a definitive agreement to be acquired by Shire, a Takeda company, for $24.
• Viridian Therapeutics Files 8-K on Financials — Aug 8, 2024 Risk: low
  Viridian Therapeutics, Inc. filed an 8-K on August 8, 2024, reporting on its results of operations and financial condition, as well as financial statements and
• Viridian Therapeutics Files 8-K — Jul 15, 2024 Risk: low
  Viridian Therapeutics, Inc. filed an 8-K on July 15, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly kno
• Viridian Therapeutics Appoints New CMO, Elects Director — Jun 20, 2024 Risk: medium
  Viridian Therapeutics, Inc. announced on June 17, 2024, the appointment of Dr. Jonathan G. Drachman as Chief Medical Officer and the election of Ms. Sarah E. Ke
• Viridian Therapeutics Files 8-K on Financials — May 8, 2024 Risk: low
  Viridian Therapeutics, Inc. filed an 8-K on May 8, 2024, reporting on its results of operations and financial condition, and including financial statements and
• Viridian Therapeutics Enters Material Definitive Agreement — Apr 16, 2024 Risk: medium
  Viridian Therapeutics, Inc. entered into a Material Definitive Agreement on April 10, 2024. The filing does not disclose the specific nature or terms of this ag
• Viridian Therapeutics Files 8-K on Financial Condition — Feb 27, 2024 Risk: low
  Viridian Therapeutics, Inc. (CIK: 0001590750) filed an 8-K on February 27, 2024, reporting on its results of operations and financial condition, as well as fina

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX